Palisade Bio (PALI) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.87% |
| Dec 31, 2025 | 57.83% |
| Sep 30, 2025 | 17.61% |
| Jun 30, 2025 | 17.34% |
| Mar 31, 2025 | 20.32% |
| Dec 31, 2024 | 23.72% |
| Sep 30, 2024 | -1.27% |
| Jun 30, 2024 | 38.35% |
| Mar 31, 2024 | 25.20% |
| Dec 31, 2023 | 13.34% |
| Sep 30, 2023 | 25.75% |
| Jun 30, 2023 | 20.67% |
| Mar 31, 2023 | 15.78% |
| Dec 31, 2022 | 7.94% |
| Sep 30, 2022 | 1.45% |
| Jun 30, 2022 | -11.35% |
| Mar 31, 2022 | -13.30% |
| Dec 31, 2021 | -8.25% |
| Sep 30, 2021 | 24.87% |
| Jun 30, 2021 | -67.77% |
| Mar 31, 2021 | -159.84% |
| Dec 31, 2020 | -39.81% |
| Sep 30, 2020 | -28.05% |
| Jun 30, 2020 | -22.89% |
| Mar 31, 2020 | -20.38% |
| Dec 31, 2019 | -19.82% |
| Sep 30, 2019 | -19.55% |
| Jun 30, 2019 | -39.41% |
| Mar 31, 2019 | -34.38% |
| Dec 31, 2018 | -6.39% |
| Sep 30, 2018 | -11.54% |
| Jun 30, 2018 | 6.95% |
| Mar 31, 2018 | 3.02% |
| Dec 31, 2017 | 4.08% |
| Sep 30, 2017 | 4.91% |
| Jun 30, 2017 | 25.32% |
| Mar 31, 2017 | 16.62% |
| Dec 31, 2016 | 46.84% |
| Sep 30, 2016 | -24.32% |
| Jun 30, 2016 | -33.15% |
| Dec 31, 2015 | -8.76% |